Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
复制标题
DOI：
10.1086/521624
复制
发表时间：
2007-10
期刊：
影响因子：
--
通讯作者：
Y. Mitsuya;Tommy F. Liu;Soo-Yon Rhee;W. J. Fessel;R. Shafer;S.-Y R
中科院分区：
文献类型：
--
作者：
Y. Mitsuya;Tommy F. Liu;Soo-Yon Rhee;W. J. Fessel;R. Shafer;S.-Y R
Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariate analyses, the number of DRV resistance-associated mutations depended on the number of previous protease inhibitors (PIs) administered and on amprenavir/fosamprenavir treatment. Most PI-treated patients should respond favorably to DRV-based salvage therapy.
